The Effect of Food Intake During Hemodialysis on Blood Pressure
Launched by MELEK AVCI · Jun 1, 2022
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
Researchers monitored the patients in two hemodialysis sessions; first meeting (T0) and second meeting (T1) which is one week later from T0. In the first meeting which is ''hemodialysis in fed state'', they ate the standard food (in clinic routine) served by the clinic at regular hours which means routine care of hemodialysis clinic. In the second meeting patients did not eat anything during hemodialysis which means intervention part of the study. Both hemodyalisis in fed and fasting state, researchers recorded patient's blood pressure were monitozied in the mid-hemodiyalsis sessions. Patie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being over the age of 18
- • Having CKD and being in the hemodialysis program
- • Having the ability to understand and speak
- • Being on HD treatment for 6 months or longer
- • Weight gain of 4 kg or less between two HD sessions
- • Standard HD is applied 3 days a week for 4 hours
- Exclusion Criteria:
- • The patient's communication difficulties, speech and understanding deterioration,
- • Being on dialysis for less than 6 months,
- • Interdialytic weight gain of more than 4kg,
- • The patient is not suitable for blood pressure measurement from the arm,
- • The patient used antihypertensive before HD,
- • Entering HD less than or more than 3 days a week,
- • More or less than 4 hours of HD input.
About Melek Avcı
Melek Avcı is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a commitment to clinical excellence and regulatory compliance, the organization collaborates with leading research institutions and medical professionals to design and implement robust clinical trials across various therapeutic areas. Melek Avcı prioritizes patient safety and data integrity, ensuring that all studies adhere to the highest ethical standards while contributing valuable insights to the scientific community. Through its strategic partnerships and commitment to innovation, Melek Avcı aims to drive progress in the healthcare sector and deliver transformative treatments to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Antalya, , Turkey
Patients applied
Trial Officials
Melek Avcı, PhD Student
Study Director
Akdeniz University
Fatma Arikan, PhD, RN
Principal Investigator
Akdeniz University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials